IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies

por Parrondo, Ricardo D., Iqbal, Madiha, Von Roemeling, Reinhard, Von Roemeling, Christina, Tun, Han W.
Publicado 2023

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

por Guidetti, Francesca, Arribas, Alberto J., Sartori, Giulio, Spriano, Filippo, Barnabei, Laura, Tarantelli, Chiara, Von Roemeling, Reinhard, Martinez, Elizabeth, Zucca, Emanuele, Bertoni, Francesco
Publicado 2023

VISTA expression and patient selection for immune-based anticancer therapy

por Martin, Alexander S., Molloy, Michael, Ugolkov, Andrey, von Roemeling, Reinhard W., Noelle, Randolph J., Lewis, Lionel D., Johnson, Melissa, Radvanyi, Laszlo, Martell, Robert E.
Publicado 2023

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

por Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
Publicado 2016

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive p...

por Forero-Torres, Andres, Infante, Jeffrey R, Waterhouse, David, Wong, Lucas, Vickers, Selwyn, Arrowsmith, Edward, He, Aiwu Ruth, Hart, Lowell, Trent, David, Wade, James, Jin, Xiaoping, Wang, Qiang, Austin, TaShara, Rosen, Michael, Beckman, Robert, von Roemeling, Reinhard, Greenberg, Jonathan, Saleh, Mansoor
Publicado 2013